S100A9 and cholangiocarcinoma: Consequently, the best model for non-CCA prediction was obtained with a combination of S100A9, MUC5AC, angiopoietin-2, and CA19-9 which resulted in a sensitivity of 82.5%, specificity of 85% and an AUC of 0.906.